Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00067080
First received: August 11, 2003
Last updated: November 16, 2016
Last verified: November 2016